[go: up one dir, main page]

CO2021005913A2 - Composiciones farmacéuticas mucoadhesivas de corticoesteroides - Google Patents

Composiciones farmacéuticas mucoadhesivas de corticoesteroides

Info

Publication number
CO2021005913A2
CO2021005913A2 CONC2021/0005913A CO2021005913A CO2021005913A2 CO 2021005913 A2 CO2021005913 A2 CO 2021005913A2 CO 2021005913 A CO2021005913 A CO 2021005913A CO 2021005913 A2 CO2021005913 A2 CO 2021005913A2
Authority
CO
Colombia
Prior art keywords
compositions
mucoadhesive
corticosteroid
pharmaceutical compositions
corticosteroids
Prior art date
Application number
CONC2021/0005913A
Other languages
English (en)
Inventor
Arnaud Grenier
Dario Carrara
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68296606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2021005913(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CO2021005913A2 publication Critical patent/CO2021005913A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen composiciones farmacéuticas mucoadhesivas de corticoesteroides, así como métodos para preparar tales composiciones farmacéuticas y métodos terapéuticos que las usan. Las composiciones normalmente comprenden un corticoesteroide en un sistema mucoadhesivo, en donde el sistema mucoadhesivo comprende un agente modificador de la reología y un vehículo para el corticoesteroide. Las composiciones son particularmente útiles para el tratamiento de afecciones inflamatorias del esófago tales como esofagitis eosinofílica o enfermedad intestinal inflamatoria.
CONC2021/0005913A 2018-10-24 2021-05-05 Composiciones farmacéuticas mucoadhesivas de corticoesteroides CO2021005913A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749878P 2018-10-24 2018-10-24
EP19150077 2019-01-02
PCT/IB2019/059079 WO2020084530A1 (en) 2018-10-24 2019-10-23 Mucoadhesive pharmaceutical compositions of corticosteroids

Publications (1)

Publication Number Publication Date
CO2021005913A2 true CO2021005913A2 (es) 2021-05-20

Family

ID=68296606

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0005913A CO2021005913A2 (es) 2018-10-24 2021-05-05 Composiciones farmacéuticas mucoadhesivas de corticoesteroides

Country Status (16)

Country Link
US (1) US20210379081A1 (es)
EP (2) EP3870226B1 (es)
JP (1) JP7479362B2 (es)
KR (1) KR20210088547A (es)
CN (1) CN113271979A (es)
AU (1) AU2019365253B2 (es)
BR (1) BR112021007140A2 (es)
CA (1) CA3116649A1 (es)
CL (1) CL2021001046A1 (es)
CO (1) CO2021005913A2 (es)
DK (1) DK3870226T3 (es)
ES (1) ES2956849T3 (es)
FI (1) FI3870226T3 (es)
MX (1) MX2021004537A (es)
PL (1) PL3870226T3 (es)
WO (1) WO2020084530A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778498B2 (en) * 1999-10-22 2004-12-09 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
CN1627951A (zh) 2001-06-07 2005-06-15 美商·邱氏顾问股份有限公司 用以预防及治疗口疮溃疡与单纯疱疹性损害的组成物及方法
US20030059446A1 (en) * 2001-09-18 2003-03-27 Kulkarni Arun B. Physically stable sprayable gel composition
US20060018937A1 (en) 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
EP1660101A4 (en) 2003-08-21 2010-02-24 Access Pharma Inc LIQUID FORMULATIONS FOR THE PREVENTION AND TREATMENT OF SLAUGHTER DISEASES AND DISORDERS
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN101939024A (zh) * 2007-11-13 2011-01-05 梅里蒂奇制药公司 用于治疗胃肠炎的组合物
SI2211896T1 (en) 2007-11-13 2018-04-30 Meritage Pharma, Inc. Ingredients for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
AU2009246870B2 (en) 2008-05-14 2013-08-01 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
EP2437743A4 (en) 2009-06-05 2012-11-28 Aciex Therapeutics Inc OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE
ES2894936T3 (es) 2010-06-24 2022-02-16 Viropharma Biologics Llc Métodos de tratamiento para la inflamación del esófago
AU2013342069B2 (en) 2012-11-09 2018-05-31 Haz Two, Llc Enema composition for treatment of ulcerative colitis having long term stability
AU2015252908B2 (en) 2014-05-01 2017-12-07 Integral Biosystems Llc Membrane-adherent self-assembled systems for treatment of ocular disorders
DE102014119576A1 (de) * 2014-12-23 2016-06-23 Ernst-Moritz-Arndt-Universität Greifswald Pharmazeutische Arzneimittelform zur Applikation auf Schleimhäuten
EP3659607A1 (en) 2015-05-04 2020-06-03 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon

Also Published As

Publication number Publication date
BR112021007140A2 (pt) 2021-07-20
FI3870226T3 (fi) 2023-09-15
PL3870226T3 (pl) 2023-12-27
WO2020084530A1 (en) 2020-04-30
EP3870226B1 (en) 2023-06-28
CN113271979A (zh) 2021-08-17
DK3870226T3 (da) 2023-09-18
US20210379081A1 (en) 2021-12-09
AU2019365253B2 (en) 2025-02-20
JP2022505535A (ja) 2022-01-14
CL2021001046A1 (es) 2022-01-07
ES2956849T3 (es) 2023-12-29
MX2021004537A (es) 2021-06-15
EP3870226A1 (en) 2021-09-01
KR20210088547A (ko) 2021-07-14
EP4233872A2 (en) 2023-08-30
CA3116649A1 (en) 2020-04-30
EP4233872A3 (en) 2023-10-11
AU2019365253A1 (en) 2021-05-27
JP7479362B2 (ja) 2024-05-08

Similar Documents

Publication Publication Date Title
CL2017002693A1 (es) Métodos para tratar infecciones por el virus filoviridae. divisional de solicitud n° 1040-2017.
ECSP21001547A (es) Formulación farmacéutica de odevixibat
CY1124554T1 (el) Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
PE20181330A1 (es) Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
PH12019502782A1 (en) Fixed dose formulations
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
BR112017018533A2 (pt) dispersões sólidas
CR20190394A (es) Compuestos de inhibidores de autotaxina
PH12017550152A1 (en) Lyophilized pharmaceutical compositions
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CO2017002472A2 (es) Formulación de acetato de abiraterona
MX370628B (es) Composiciones y metodos para tratar las espinillas.
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
MX378931B (es) Metodos para tratar y prevenir enfermedades de inestabilidad vascular.
CO2021005913A2 (es) Composiciones farmacéuticas mucoadhesivas de corticoesteroides
EA201891352A1 (ru) Вспенивающиеся композиции, содержащие кортикостероид, и способ их производства
MX2020003830A (es) Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos.